SEARCH

SEARCH BY CITATION

References

  • BERDYSHEV, E., BOICHOT, E., CORBEL, M., GERMAIN, N. & LAGENTE, V. (1998). Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci., 63, PL125129.
  • BROWN, J.M., GROSSO, M.A., TERADA, L.S., WHITMAN, G.J., BANERJEE, A., WHITE, C.W., HARKEN, A.H. & REPINE, J.E. (1989). Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc. Natl. Acad. Sci. U.S.A., 86, 25162520.
  • GEBREMEDHIN, D., LANGE, A.R., CAMPBELL, W.B., HILLARD, C.J. & HARDER, D.R. (1999). Cannabinoid CB1 receptor of cat cerebral arteriol muscle funtions to inhibit L-type Ca2+ channel current. Am. J. Physiol., 276, H2085H2093.
  • GALIEGUE, S., MARY, S., MARCHAND, J., DUSSOSSOY, D., CARRIERE, D., CARAYON, P., BOUABOULA, M., SHIRE, D., LE FUR, G. & CASELLAS, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 232, 5461.
  • JEON, Y.J., YANG, K.H., PULASKI, J.T. & KAMINSKI, N.E. (1996). Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol. Pharmacol., 50, 334341.
  • LAKE, K.D., COMPTON, D.R., VARGA, K., MARTIN, B.R. & KUNOS, G. (1997). Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther., 281, 10301037.
  • LIU, J., GAO, B., MIRSHAHI, F., SANYAL, A.J., KHANOLKAR, A.D., MAKRIYANNIS, A. & KUNOS, G. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J., 15, 835840.
  • MOLDERINGS, G.J., LIKUNGU, J. & GOTHERT, M. (1999). Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn Schmiedebergs Arch. Pharmacol., 360, 157164.
  • NIEDERHOFFER, N. & SZABO, B. (2000). Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J. Pharmacol. Exp. Ther., 294, 707713.
  • PIOMELLI, D., GIUFFRIDA, A., CALIGNANO, A., RODRÍGUEZ, D.E. & FONSECA, F. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sc., 21, 218223.
  • RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NELIAT, G. & CAPUT, D. (1994). SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 22, 240244.
  • RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J.C. & LE FUR, G.L. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644650.
  • ROSS, R.A., BROCKIE, H.C. & PERTWEE, R.G. (2000). Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoid and palmitoyl-ethanolamide. Eur. J. Pharmacol., 401, 121130.
  • SCHMID, P.C., SCHWARTZ, K.D., SMITH, C.N., KREBSBACH, R.J., BERDYSHEV, E.V. & SCHMID, H.H. (2000). A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chem. Phys. Lipids, 104, 185191.
  • SMITH, S.R., TERMINELLI, C. & DENHARDT, G. (2000). Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther., 293, 136150.
  • VARGA, K., WAGNER, J.A., BRIDGEN, D.T. & KUNOS, G. (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J., 12, 10351044.
  • WAKSMAN, Y., OLSON, J.M., CARLISLE, S.J. & CABRAL, G.A. (1999). The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther., 288, 13571366.
  • YANG, B.C., CHEN, L.Y., SALDEEN, T.G. & MEHTA, J.L. (1997). Reperfusion injury in the endotoxin-treated rat heart: reevaluation of the role of nitric oxide. Br. J. Pharmacol., 120, 305311.
  • ZHU, L.X., SHARMA, S., STOLINA, M., GARDNER, B., ROTH, M.D., TASHKIN, D.P. & DUBINETT, S.M. (2000). Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol., 165, 373380.